Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CRL · Entity 3398 | Corporate Executive VP & CCO | November 07, 2024 | November 08, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Report date November 07, 2024 · Filed November 08, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 23,337 |
Reported balance
After 2024-11-07 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2024-11-07 · Gift · Disposed 470 · Balance 23,337 F1: Reflects the exempt transfer pursuant to Rule 16a-13 of 965 shares held by the reporting person to William D. Barbo Revocable Trust. |
| Common StockSEC Table I · non-derivative | Direct | 2,468 |
Reported balance
Holding disclosure · report date 2024-11-07 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 2,468 |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the exempt transfer pursuant to Rule 16a-13 of 965 shares held by the reporting person to William D. Barbo Revocable Trust.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 06, 2017 Filed Mar 7, 2017 20:47 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 500 | $87.82 | $43,910.00 |
DisclosureSEC source: 0001127602-17-010548 · form4.xml · nonDerivative · entry 22 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,490 Read SEC document |
| March 06, 2017 Filed Mar 7, 2017 20:47 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 940 | $87.80 | $82,532.00 |
DisclosureSEC source: 0001127602-17-010548 · form4.xml · nonDerivative · entry 21 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,990 Read SEC document |
| March 06, 2017 Filed Mar 7, 2017 20:47 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 134 | $87.80 | $11,764.53 |
DisclosureSEC source: 0001127602-17-010548 · form4.xml · nonDerivative · entry 20 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,930 Read SEC document |
| March 06, 2017 Filed Mar 7, 2017 20:47 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 300 | $87.79 | $26,337.00 |
DisclosureSEC source: 0001127602-17-010548 · form4.xml · nonDerivative · entry 19 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,064 Read SEC document |
| March 06, 2017 Filed Mar 7, 2017 20:47 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 90 | $87.79 | $7,900.65 |
DisclosureSEC source: 0001127602-17-010548 · form4.xml · nonDerivative · entry 18 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,364 Read SEC document |
| March 06, 2017 Filed Mar 7, 2017 20:47 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,500 | $87.78 | $131,670.00 |
DisclosureSEC source: 0001127602-17-010548 · form4.xml · nonDerivative · entry 17 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,454 Read SEC document |
| March 06, 2017 Filed Mar 7, 2017 20:47 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 10 | $87.78 | $877.75 |
DisclosureSEC source: 0001127602-17-010548 · form4.xml · nonDerivative · entry 16 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,954 Read SEC document |
| March 06, 2017 Filed Mar 7, 2017 20:47 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,000 | $87.77 | $87,770.00 |
DisclosureSEC source: 0001127602-17-010548 · form4.xml · nonDerivative · entry 15 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,964 Read SEC document |
| March 06, 2017 Filed Mar 7, 2017 20:47 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $87.77 | $8,776.50 |
DisclosureSEC source: 0001127602-17-010548 · form4.xml · nonDerivative · entry 14 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,964 Read SEC document |
| March 06, 2017 Filed Mar 7, 2017 20:47 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,102 | $87.76 | $96,711.52 |
DisclosureSEC source: 0001127602-17-010548 · form4.xml · nonDerivative · entry 13 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,064 Read SEC document |
| March 06, 2017 Filed Mar 7, 2017 20:47 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 400 | $87.75 | $35,100.00 |
DisclosureSEC source: 0001127602-17-010548 · form4.xml · nonDerivative · entry 12 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,166 Read SEC document |
| March 06, 2017 Filed Mar 7, 2017 20:47 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,000 | $87.74 | $87,740.00 |
DisclosureSEC source: 0001127602-17-010548 · form4.xml · nonDerivative · entry 11 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,566 Read SEC document |
| March 06, 2017 Filed Mar 7, 2017 20:47 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $87.74 | $8,773.50 |
DisclosureSEC source: 0001127602-17-010548 · form4.xml · nonDerivative · entry 10 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,566 Read SEC document |
| March 06, 2017 Filed Mar 7, 2017 20:47 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 900 | $87.73 | $78,957.00 |
DisclosureSEC source: 0001127602-17-010548 · form4.xml · nonDerivative · entry 9 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,666 Read SEC document |
| March 06, 2017 Filed Mar 7, 2017 20:47 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 700 | $87.72 | $61,404.00 |
DisclosureSEC source: 0001127602-17-010548 · form4.xml · nonDerivative · entry 8 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,566 Read SEC document |
| March 06, 2017 Filed Mar 7, 2017 20:47 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $87.71 | $17,542.00 |
DisclosureSEC source: 0001127602-17-010548 · form4.xml · nonDerivative · entry 7 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,266 Read SEC document |
| March 06, 2017 Filed Mar 7, 2017 20:47 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 506 | $87.70 | $44,376.20 |
DisclosureSEC source: 0001127602-17-010548 · form4.xml · nonDerivative · entry 6 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,466 Read SEC document |
| March 06, 2017 Filed Mar 7, 2017 20:47 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 400 | $87.69 | $35,076.00 |
DisclosureSEC source: 0001127602-17-010548 · form4.xml · nonDerivative · entry 5 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,972 Read SEC document |
| March 06, 2017 Filed Mar 7, 2017 20:47 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 3,015 | $73.70 | $222,205.50 |
DisclosureSEC source: 0001127602-17-010548 · form4.xml · nonDerivative · entry 4 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,372 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2017 Filed Mar 7, 2017 20:47 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 4,315 | $76.67 | $330,831.05 |
DisclosureSEC source: 0001127602-17-010548 · form4.xml · nonDerivative · entry 3 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,357 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2017 Filed Mar 7, 2017 20:47 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 1,825 | $59.41 | $108,423.25 |
DisclosureSEC source: 0001127602-17-010548 · form4.xml · nonDerivative · entry 2 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,042 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2017 Filed Mar 7, 2017 20:47 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 2,293 | $40.40 | $92,637.20 |
DisclosureSEC source: 0001127602-17-010548 · form4.xml · nonDerivative · entry 1 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,217 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 20:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 218 | $89.64 | $19,541.52 |
DisclosureSEC source: 0001127602-17-009172 · form4.xml · nonDerivative · entry 2 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,924 Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 20:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 231 | $88.05 | $20,339.55 |
DisclosureSEC source: 0001127602-17-009172 · form4.xml · nonDerivative · entry 1 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,142 Read SEC document |
| February 26, 2017 Filed Feb 28, 2017 13:34 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 289 | $88.05 | $25,446.45 |
DisclosureSEC source: 0001127602-17-008821 · form4.xml · nonDerivative · entry 2 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,373 Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 13:34 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 13,969 | $0.00 Strike: $88.05 | $0.00 |
DisclosureSEC source: 0001127602-17-008821 · form4.xml · derivative · entry 3 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,969 Underlying: Common Stock · 13,969 shares Expires 2022-02-24 F2 · derivative.exercise_date: Stock options vest as follows: 3,492 options vest one (1) year from the date of grant, 3,492 options vest two (2) years from the date of grant, 3,492 options vest three (3) years from the date of grant, and 3,493 options vest four (4) years from the date of grant. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 13:34 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 2,899 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-008821 · form4.xml · nonDerivative · entry 1 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,662 F1 · security: Consists of 2,899 unvested restricted stock units that vest as follows: 724 shares vest one (1) year from the date of issuance, 725 shares vest two (2) years from the date of issuance, 725 shares vest three (3) years from the date of issuance, and 725 shares vest four (4) years from the date of issuance. Read SEC document |
| February 22, 2017 Filed Feb 23, 2017 13:47 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 905 | $88.40 | $80,002.00 |
DisclosureSEC source: 0001127602-17-007918 · form4.xml · nonDerivative · entry 1 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,763 Read SEC document |
| January 31, 2017 Filed Feb 2, 2017 13:25 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 3,046 | $78.38 | $238,745.48 |
DisclosureSEC source: 0001127602-17-003433 · form4.xml · nonDerivative · entry 2 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,668 Read SEC document |
| January 31, 2017 Filed Feb 2, 2017 13:25 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 9,249 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-003433 · form4.xml · nonDerivative · entry 1 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,714 F1 · kind: Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on February 28, 2014. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.